| https://link.springer.com/article/10.1208/s12248-023-00842-1 |
- Uma Kavita,
- Kefeng Sun,
- Manuela Braun,
- Wibke Lembke,
- Hardik Mody,
- John Kamerud,
- Tong-Yuan Yang,
- Inka V. Braun,
- Xiaodong Fang,
- Wei Gao,
- Swati Gupta,
- Magdalena Hofer,
- Michael Z. Liao,
- LiNa Loo,
- Fraser McBlane,
- Karelle Menochet,
- Kay-Gunnar Stubenrauch,
- Vijay V. Upreti,
- Adam Vigil,
- Christopher M. Wiethoff,
- Cindy Q. Xia,
- Xu Zhu,
- Vibha Jawa &
- Nagendra Chemuturi
Interest and efforts to use recombinant adeno-associated viruses (AAV) as gene therapy delivery tools to treat disease have grown exponentially. However, gaps in understanding of the pharmacokinetics/pharmacodynamics (PK/PD) and disposition of this modality exist. This position paper comes from the Novel Modalities Working Group (WG), part of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ). The pan-industry WG effort focuses on the nonclinical PK and clinical pharmacology aspects of AAV gene therapy and related bioanalytical considerations.
Traditional PK concepts are generally not applicable to AAV-based therapies due to the inherent complexity of a transgene-carrying viral vector, and the multiple steps and analytes involved in cell transduction and transgene-derived protein expression. Therefore, we explain PK concepts of biodistribution of AAV-based therapies and place key terminologies related to drug exposure and PD in the proper context. Factors affecting biodistribution are presented in detail, and guidelines are provided to design nonclinical studies to enable a stage-gated progression to Phase 1 testing. The nonclinical and clinical utility of transgene DNA, mRNA, and protein analytes are discussed with bioanalytical strategies to measure these analytes. The pros and cons of qPCR vs. ddPCR technologies for DNA/RNA measurement and qualitative vs. quantitative methods for transgene-derived protein are also presented. Last, best practices and recommendations for use of clinical and nonclinical data to project human dose and response are discussed. Together, the manuscript provides a holistic framework to discuss evolving concepts of PK/PD modeling, bioanalytical technologies, and clinical dose selection in gene therapy.
To view the full article through your AAPS membership:
Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal. Click or tap if you trust this link." rel="noopener">https://www.aaps.org/education-and-research/journals/the-aaps-journal
Enter your AAPS credentials
Click "Member Access to Journals"
Click on the The AAPS Journal cover.
Copy and paste the url into the "Search" box, and click search
The full article should appear.
Follow The AAPS Journal via Twitter: https://twitter.com/theaapsjournal
and by Linkedin, https://www.linkedin.com/showcase/theaapsjournal/
------------------------------
Ho-Leung Fung Ph.D., FAAPS
Editor-in-Chief
University at Buffalo
Sarasota FL
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------